Reviva Pharmaceuticals Progresses with Global Schizophrenia Trial
Company Announcements

Reviva Pharmaceuticals Progresses with Global Schizophrenia Trial

Reviva Pharmaceuticals Holdings (RVPH) just unveiled an announcement.

Reviva Pharmaceuticals Holdings, Inc. has provided an update on the progress of their RECOVER trial, which is assessing the safety and efficacy of brilaroxazine for treating schizophrenia. The trial is advancing as planned across the USA, Europe, and Asia with 358 patients enrolled, 223 currently receiving treatment. Notably, 23 patients have completed a full year of treatment, which is crucial as data from 100 such patients is needed for the New Drug Application to the FDA. Reviva anticipates wrapping up this year-long safety study by the fourth quarter of 2024.

See more insights into RVPH stock on TipRanks’ Stock Analysis page.

Related Articles
Austin AngeloRVPH Earnings Report this Week: Is It a Buy, Ahead of Earnings?
TheFlyReviva Pharmaceuticals initiated with a Buy at EF Hutton
TheFlyReviva Pharmaceuticals announces vocal biomarker data from RECOVER trial
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App